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Abstract
Background—Only 13% of HIV-positive young adults are estimated to be virally suppressed 
and, even among those receiving medical care, HIV-positive young adults are less likely than older 
adults to take antiretroviral therapy (ART), be adherent, and be virally suppressed. We sought to 
examine trends in treatment and health outcomes from 2009 to 2013 among HIV-positive young 
adults (ages 18–24) in care.
Setting—The Medical Monitoring Project (MMP) is a complex sample survey of HIV-infected 
adults receiving medical care in the United States.
Methods—We used weighted interview and medical record data collected 06/2009-05/2014 to 
estimate trends in the prevalence of ART prescription, adherence, side effects, single-tablet ART 
regimens, regular care utilization and viral suppression among young adults.
Results—From 2009 to 2013, there were significant increases in ART prescription (76% to 87%) 
and the proportion of young adults taking ART who reported taking single-tablet regimens (49% 
to 62%). There was no significant change in adherence, side effects, or regular care utilization. 
Although viral suppression at last test did not change (65% at both time periods), the proportion of 
young adults who were sustainably virally suppressed significantly increased (29% to 46%). 
Accounting for ART prescription and single-tablet regimens use attenuated the sustained viral 
suppression trend.
Conclusions—Although the level of viral suppression among young adults in care remains 
suboptimal, the observed increases in ART prescription and sustained viral suppression may be 
cause for optimism regarding efforts to improve outcomes for this vulnerable population.
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HIV viral suppression is key to reducing the risk of HIV transmission, morbidity, and 
mortality (1, 2) and thus it is crucial for prevention and care efforts. Only 13% of HIV-
positive young adults are estimated to be virally suppressed (3) and, even among those 
receiving medical care, HIV-positive young adults are less likely than older adults to take 
antiretroviral therapy (ART), be adherent, and be virally suppressed (4–6). Agwu and 
colleagues found evidence of increasing ART use and decreasing viremia from 2002 to 2010 
among a cohort of youth living with HIV who were perinatally-infected (7). Recent 
developments in HIV care and treatment may have improved levels of viral suppression 
more broadly among young adults. Clinical guidelines now recommend the universal 
prescription of ART and simpler, more tolerable ART regimens that may be more forgiving 
of non-adherence have been developed (8–10). There has also been enhanced focus across 
medical, public health, and community groups on improving the HIV care continuum among 
youth (11–13). However, the effect of these developments among HIV-positive youth 
nationally is unknown.
This analysis was guided by the following questions: have recent developments in HIV care 
and treatment been accompanied by increased ART prescription, adherence, and care 
utilization among young adults in care? If so, have these changes contributed to 
improvements in viral suppression? To answer these questions, we estimated temporal trends 
in these factors among HIV-positive young adults in care in the United States from 2009 to 
2013.
Methods
Medical Monitoring Project (MMP)
We analyzed pooled data from the 2009–2013 cycles of the Medical Monitoring Project 
(MMP), an HIV surveillance system designed to produce annual nationally representative 
cross-sectional estimates of behavioral and clinical characteristics of HIV-infected adults 
receiving medical care in the United States and Puerto Rico. MMP methods, including 
sampling, weighting procedures, and response rates, have been described in detail elsewhere 
(14). During these years, MMP used a three-stage, probability-proportional-to-size sampling 
method. First, U.S. states and one territory were sampled, then facilities providing outpatient 
HIV care in those areas, and finally, eligible HIV-infected patients. All sampled states and 
territories participated in every cycle. The facility response rate ranged from 76–85% and 
the patient response rate ranged from 49–55%. Eligible persons were HIV-infected, were 
aged 18 years or older, and received medical care in participating facilities between January 
and April in the cycle year for which they were sampled. Interview and medical record 
abstraction data were collected June 2009 through May 2014. Data were weighted on the 
basis of known probabilities of selection at state or territory, facility, and patient levels (15). 
In addition, predictors of nonresponse were determined from analysis of data from sampled 
facilities and patients, and data were then weighted to adjust for non-response, after 
established methods (16, 17). Predictors of nonresponse varied by cycle year and project 
area, but in general facility size, private practice, male gender, younger age, race/ethnicity, 
Beer et al. Page 2













and shorter time since HIV diagnosis were associated with nonresponse and informed the 
weighting classes for the data.
In accordance with the federal human subjects protection regulations (18) and guidelines for 
defining public health research (19), MMP was determined to be a non-research, public 
health surveillance activity used for disease control program or policy purposes. 
Participating states or territories and facilities obtained local institutional review board 
approval to conduct MMP if required locally. Informed consent was obtained from all 
interviewed participants.
Analytic methods
In this analysis we included 636 young adults aged 18–24 who were receiving HIV care in 
the United States. The sample sizes and proportions of the total MMP sample of all persons 
receiving HIV care by year were 2009, n=107 (16%); 2010, n=125 (21%); 2011, n=127 
(21%); 2012, n=144 (22%); and 2013, n=133 (21%). We estimated weighted percentages by 
year and used bivariate linear regression (ordinary least squares) to estimate trends from 
2009 to 2013 in 1) ART prescription during the past 12 months, 2) regular care utilization (at 
least 1 viral load in each 6 month period during the past 12 months), 3) 100% adherence to 
ART doses during the past 3 days, 4) being bothered by ART side effects in the past 30 days, 
5) taking a once-daily single tablet ART regimen, 6) viral suppression (<200 copies/mL at 
last test), and 7) sustained viral suppression (<200 copies/mL at all tests during past 12 
months). All measures were derived from medical record reviews except the adherence, side 
effects, and single-tablet regimen measures, which were self-reported. Beta-coefficients for 
year represent the average percentage point change from one year to the next. We considered 
trends to be statistically significant when P<0.05. For the viral suppression measures that 
showed a significant trend, we used multivariate linear regression to assess how much 
change in viral suppression was mediated by change over time in covariates that also 
significantly increased over the time period. We also estimated trends in selected 
sociodemographic characteristics collected by interview (black non-Hispanic race versus 
other racial/ethnic groups, male gender versus female or transgender, homosexual or 
bisexual identity versus heterosexual, less than high school education versus higher, at or 
below household poverty guideline versus over, uninsured or only Ryan White HIV/AIDS 
Program coverage versus private or public insurance, 5 or more years since HIV diagnosis 
versus less than 5 years) and HIV disease stage derived from medical record review (AIDS 
or nadir CD4+ 0–199 versus no AIDS and nadir CD4+ 200+) to evaluate their roles as 
potential confounders of change over time in viral suppression. All data were weighted for 
unequal selection probabilities and non-response.
Results
The characteristics of HIV-positive young adults in care in the United States during 2009–
2013 have been reported elsewhere (4), but overall among the pooled dataset (n=636) 43% 
(95% confidence interval [CI] 37–50) were black men. The majority had a gay or bisexual 
identity (62%, CI 57–67) and were living in households at or below the poverty level (62%, 
CI 56–66). Approximately 35% (CI 28–41) were uninsured or only had Ryan White HIV/
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AIDS Program coverage. Over the 12 months before interview, 14% (CI 10–18) reported 
being homeless and 11% (CI 8–14) had been incarcerated. Most were diagnosed with HIV 
after the age of 10 years (88%, CI 84–91), and three-quarters had been diagnosed for less 
than 5 years (75%, CI 70–80). There were no significant changes in sociodemographic 
characteristics, time since HIV diagnosis, and HIV disease stage during 2009–2013 with the 
exception of an increasing proportion of men over the time period (65% in 2009 to 74% in 
2013, βTREND=0.03 PTREND=0.03, Table 1).
ART prescription among young adults significantly increased from 76% in 2009 to 87% in 
2013 (βTREND=0.04 PTREND=0.01; Table 2). Among those taking ART, however, ART 
adherence and reported problems with side effects did not significantly change over the 
period. The proportion of young adults taking ART who reported taking a single-tablet 
regimen significantly increased from 49% in 2009 to 62% in 2013 (βTREND=0.04 
PTREND=0.04). There was no significant change in regular care utilization over the period.
Although viral suppression at last test did not change over the time period (65% in 2009 to 
65% in 2013, βTREND=0.02 PTREND=0.22), the proportion of young adults who were 
sustainably virally suppressed significantly increased (29% in 2009 to 46% in 2013, 
βTREND=0.05 PTREND=<0.01. Figure 1 illustrates these findings. The proportion of young 
adults who were virally suppressed at their last test and had sustained viral suppression 
increased from 2009 to 2013, but there was no concomitant increase in those who were 
virally suppressed only at their last test. Instead, the proportion who were only virally 
suppressed at their last visit decreased over the time period. Adjusting for the increasing 
proportion of men among young adults over the time period did not change the sustained 
viral suppression trend (adjusted βTREND=0.05 PTREND=<0.01; data not shown in table). 
Accounting for ART prescription somewhat attenuated the sustained viral suppression trend 
(adjusted βTREND=0.04, PTREND=0.02), suggesting that some of the increase in sustained 
viral suppression was mediated by increased ART prescription. Adding to the model a 
variable measuring whether the person prescribed ART reported taking a single-tablet 
regimen further attenuated the sustained viral suppression trend (adjusted βTREND =0.03, 
PTREND=0.04).
Discussion
We found significant improvements in sustained viral suppression from 2009 to 2013 among 
young adults in care, which were partially attributable to increases in the proportions of 
young adults prescribed ART and taking single-tablet regimens. However, we found no 
significant trend in viral suppression at last test. In any given year, only approximately 2/3 of 
young adults in HIV care were virally suppressed at last test, well short of the National HIV/
AIDS Strategy (NHAS) 80% viral suppression goal for all diagnosed persons (13). However, 
increasingly more young adults were able to maintain suppression, and a smaller proportion 
were only suppressed at their last test, which indicates some progress has been made in 
improving health among this disproportionately affected population.
Our data show that between 2009 and 2013 providers were more likely to prescribe ART to 
young adults in later years and also more likely to prescribe single-tablet regimens, both of 
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which were associated with increased levels of sustained viral suppression. During this time 
period, guidelines for initiating ART steadily moved away from using CD4 count as a 
criterion for initiation (8), and our data may reflect increasing provider adoption of these 
guidelines. Providers have often cited concerns about treatment readiness and other barriers 
to adherence as a reason to defer ART initiation for otherwise clinically-eligible young 
people (20, 21), who on average report lower adherence than older persons (4). However, 
providers may have grown less concerned about nonadherence as a reason to defer therapy 
among young adults because of the increasing evidence of the benefits of early ART and the 
availability of better regimen options that are more forgiving of nonadherence (9). The 
development of multiple single-tablet regimens during this time period, which are associated 
with better adherence, lower cost and increased patient satisfaction (10) also may have 
facilitated provider prescription of these regimens among young adults.
Despite improvements in sustained viral suppression, the prevalence of viral suppression at 
last test remained stable from 2009 to 2013. This stability may be due to lack of 
improvement in adherence among young adults. Although one might expect that the increase 
in use of single-tablet regimens would be accompanied by increased adherence, it is 
important to note that our measure of adherence is self-reported and limited to the past three 
days, which may overestimate adherence and limit our ability to detect differences among 
persons due to ceiling effects (22). It is also possible that the use of single-tablet regimens 
has a greater effect on non-persistence (treatment discontinuation) rather than non-adherence 
(treatment interruption over a specified time period); Sweet and colleagues found that non-
persistence was higher among persons taking multi-tablet regimens compared to single-
tablet regimens (23).
Despite the limitations of the adherence measure, the lack of improvements observed among 
young adults suggest that wider development and implementation of effective strategies to 
improve adherence among young persons may be warranted. A recent systematic review of 
adherence interventions for youth found that most interventions were small pilots that need 
to be replicated; their findings indicated that a phone-based counseling approach with 
adherence monitors and weekly individual and family counseling may be effective strategies 
for improving adherence in this population (24). Our findings on the contribution of single-
tablet regimens to improvements in sustained viral suppression suggest that simplifying 
regimens might be an effective strategy to increase viral suppression among young adults. In 
addition, when selecting regimens providers may need to consider the relatively high 
prevalence of side effects reported by young adults, which did not decrease over the time 
period. The development of injectable long-acting antitretrovirals may also prove to be a 
promising strategy for increasing viral suppression among this population (25).
This analysis has limitations. First, our patient response rates ranged from 49–55%, although 
our use of population-based sampling methods and weighting adjustments for non-response 
should reduce bias (26), and the MMP population is demographically similar to all HIV-
diagnosed persons in the United States (27). Another potential limitation to the 
generalizability of our estimates is our selection of patients based on receipt of HIV care in 
the first 4 months of the calendar year. However, Sullivan and colleagues found that 88% of 
HIV patients had a medical visit in the first 4 months of the year, though there were some 
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clinical differences in this group compared to those seen later in the year (28). We should 
note, however, that our findings regarding trends should not be affected by these limitations, 
as they were consistent throughout the time period. As noted earlier, our adherence measure 
is self-reported and only captures the past three days, which may overestimate adherence 
because of measurement error resulting from social desirability bias and limit our ability to 
assess changes in adherence due to ceiling effects (22). In addition, we did not assess other 
potential explanatory factors for changes in viral suppression, such as changes in ART 
regimens. Finally, we cannot assess temporality between the self-reported interview 
measures and viral suppression.
In conclusion, we saw significant improvements in sustained viral suppression among HIV-
positive young adults in care in the United States, which seem to be partially attributable to 
increases in ART prescription and use of single tablet regimens. However, it is important to 
note that the level of viral suppression among young adults in care remains low; it falls short 
of the NHAS goals and is significantly lower than is found for older age groups (13). 
Nevertheless, the observed increases in ART prescription and sustained viral suppression 
among young adults in care are encouraging, and suggest there may be cause for optimism 
regarding efforts to improve outcomes for this vulnerable population.
Acknowledgments
The following are the contributions of the authors to the study: L.B.: study conception, data analysis, and wrote the 
article; C.L.M., H.B., and R.L.S.: study conception and edited the article. We thank participating MMP patients, 
facilities, project areas, and Provider and Community Advisory Board members. We also acknowledge the 
contributions of the Clinical Outcomes Team and Behavioral and Clinical Surveillance Branch at CDC and the 
MMP project areas (http://www.cdc.gov/hiv/statistics/systems/mmp/resources.html).
Sources of funding: Funding for the Medical Monitoring Project is provided by the Centers for Disease Control and 
Prevention.
References
1. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. 
Antiretroviral Therapy for the Prevention of HIV-1 Transmission. The New England journal of 
medicine. 2016
2. May MT, Gompels M, Delpech V, Porter K, Orkin C, Kegg S, et al. Impact on life expectancy of 
HIV-1 positive individuals of CD4+ cell count and viral load response to antiretroviral therapy. 
AIDS (London, England). 2014; 28(8):1193–202.
3. Bradley, H., Hall, HI., Wolitski, R., Handel, M., Stone, A., LaFlam, M., et al. Vital Signs: HIV 
Diagnosis, Care, and Treatment Among Persons Living with HIV — United States, 2011. 2014 Nov 
28. 2014 Report No.: Contract No.: 47
4. Beer L, Mattson CL, Shouse RL, Prejean J. Receipt of clinical and prevention services, clinical 
outcomes, and sexual risk behaviors among HIV-infected young adults in care in the United States. 
AIDS care. 2016:1–5.
5. Zanoni BC, Mayer KH. The adolescent and young adult HIV cascade of care in the United States: 
exaggerated health disparities. AIDS patient care and STDs. 2014; 28(3):128–35. [PubMed: 
24601734] 
6. Kahana SY, Fernandez MI, Wilson PA, Bauermeister JA, Lee S, Wilson CM, et al. Rates and 
correlates of antiretroviral therapy use and virologic suppression among perinatally and behaviorally 
HIV-infected youth linked to care in the United States. Journal of acquired immune deficiency 
syndromes (1999). 2015; 68(2):169–77. [PubMed: 25590270] 
Beer et al. Page 6













7. Agwu AL, Fleishman JA, Rutstein R, Korthuis PT, Gebo K. Changes in Advanced 
Immunosuppression and Detectable HIV Viremia Among Perinatally HIV-Infected Youth in the 
Multisite United States HIV Research Network. Journal of the Pediatric Infectious Diseases Society. 
2013; 2(3):215–23. [PubMed: 26619475] 
8. Panel on Antiretroviral Guidelines for Adults and Adolescents. [Accessed July 20, 2016] Guidelines 
for the use of antiretroviral agents in HIV-1-infected adults and adolescents. 2016. [Available from: 
http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf
9. Shuter J. Forgiveness of non-adherence to HIV-1 antiretroviral therapy. The Journal of antimicrobial 
chemotherapy. 2008; 61(4):769–73. [PubMed: 18256112] 
10. Truong WR, Schafer JJ, Short WR. Once-Daily, Single-Tablet Regimens For the Treatment of 
HIV-1 Infection. P & T : a peer-reviewed journal for formulary management. 2015; 40(1):44–55. 
[PubMed: 25628507] 
11. Centers for Disease Control and Prevention. HIV Among Youth. 2015. [Available from: http://
www.cdc.gov/hiv/group/age/youth/index.html
12. Koenig LJ, Hoyer D, Purcell DW, Zaza S, Mermin J. Young People and HIV: A Call to Action. 
American journal of public health. 2016:e1–e4.
13. White House Office of National AIDS Policy. National HIV/AIDS Strategy for the United States: 
Updated to 2020 Washington, DC: White House Office of National AIDS Policy. 2015. [Available 
from: https://www.aids.gov/federal-resources/national-hiv-aids-strategy/nhas-update.pdf
14. Bradley, H., Frazier, E., Huang, P., Fagan, J., Do, A., Mattson, C., et al. Behavioral and Clinical 
Characteristics of Persons Receiving Medical Care for HIV Infection Medical Monitoring Project 
United States, 2010. Atlanta, GA: 2014 Oct. 2014. Report No
15. Harding, L.Iachan, R.Johnson, C.Kyle, T., Skarbinski, J., editors. Weighting Methods for the 2010 
Data Collection Cycle of the Medical Monitoring Project. Joint Statistical Meeting; 2013 August 3 
– 8, 2013; Montréal, QC, H2Z 1H2, Canada. 2013. 
16. Särndal, C-E., Lundström, S. Estimation in Surveys with Nonresponse. Chichester: John Wiley & 
Sons; 2005. 
17. Heeringa, S., West, BT., Berglund, PA. Applied survey data analysis. Boca Raton, FL: Taylor & 
Francis; 2010. 
18. [Accessed February 4, 2014] Protection of Human Subjects, US Federal Code Title 45 Part 46. 
2009. [Available from: http://www.hhs.gov/ohrp/humansubjects/guidance/45cfr46.html
19. Centers for Disease Control and Prevention. [Accessed February 4, 2014] Distinguishing Public 
Health Research and Public Health Nonresearch. 2010. [Available from: http://www.cdc.gov/od/
science/integrity/docs/cdc-policy-distinguishing-public-health-research-nonresearch.pdf
20. Gagliardo C, Murray M, Saiman L, Neu N. Initiation of antiretroviral therapy in youth with HIV: a 
U.S.-based provider survey. AIDS patient care and STDs. 2013; 27(9):498–502. [PubMed: 
23937549] 
21. Lee L, Rand CS, Ellen JM, Agwu AL. Factors informing HIV providers' decisions to start 
antiretroviral therapy for young people living with behaviorally acquired HIV. The Journal of 
adolescent health : official publication of the Society for Adolescent Medicine. 2014; 55(3):358–
65. [PubMed: 24794054] 
22. Stirratt MJ, Dunbar-Jacob J, Crane HM, Simoni JM, Czajkowski S, Hilliard ME, et al. Self-report 
measures of medication adherence behavior: recommendations on optimal use. Translational 
behavioral medicine. 2015; 5(4):470–82. [PubMed: 26622919] 
23. Sweet D, Song J, Zhong Y, Signorovitch J. Real-world medication persistence with single versus 
multiple tablet regimens for HIV-1 treatment. Journal of the International AIDS Society. 2014; 
17(4 Suppl 3):19537. [PubMed: 25394046] 
24. Shaw S, Amico KR. Antiretroviral Therapy Adherence Enhancing Interventions for Adolescents 
and Young Adults 13–24 Years of Age: A Review of the Evidence Base. Journal of acquired 
immune deficiency syndromes (1999). 2016; 72(4):387–99. [PubMed: 26959190] 
25. Margolis, DA., Gonzalez-Garcia, J., Stellbrink, H., Eron, JJ., Yazdanpanah, Y., Griffith, S., et al. 
Cabotegravir+Rilpivirine as Long-Acting Maintenance Therapy: LATTE-2 Week 32 Results. 
Conference on Retroviruses and Opportunistic Infections (CROI); Boston. 2016. Abstract 31LB
Beer et al. Page 7













26. Groves RM. Nonresponse Rates and Nonresponse Bias in Household Surveys. Public Opinion 
Quarterly. 2006; 70(5):646–74.
27. Buchacz K, Frazier EL, Hall HI, Hart R, Huang P, Franklin D, et al. A Matter of Perspective: 
Comparison of the Characteristics of Persons with HIV Infection in the United States from the 
HIV Outpatient Study, Medical Monitoring Project, and National HIV Surveillance System. The 
open AIDS journal. 2015; 9:123–33. [PubMed: 26793282] 
28. Sullivan PS, Juhasz M, McNaghten AD, Frankel M, Bozzette S, Shapiro M. Time to first annual 
HIV care visit and associated factors for patients in care for HIV infection in 10 US cities. AIDS 
care. 2011; 23(10):1314–20. [PubMed: 21939408] 
Beer et al. Page 8














Viral suppression among HIV-positive young adults receiving medical care by year --- 
Medical Monitoring Project, 2009–2013
Viral suppression, undetectable or <200 copies/mL.
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